James Nagarajah

List of Publications by Year
in descending order

74 papers	1,996 citations	218677 26 h-index	276875 41 g-index
83 all docs	83 docs citations	83 times ranked	2477 citing authors

#	Article	IF	Citations
1	Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma. Clinical Nuclear Medicine, 2012, 37, 121-127.	1.3	115
2	Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. Journal of Clinical Investigation, 2016, 126, 4119-4124.	8.2	102
3	Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer. Investigative Radiology, 2015, 50, 505-513.	6.2	84
4	Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. European Journal of Radiology, 2016, 85, 459-465.	2.6	81
5	Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using ¹²⁴I PET Imaging. Journal of Nuclear Medicine, 2014, 55, 1759-1765.	5.0	78
6	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 505-510.	6.4	76
7	Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸F-FDG PET: Feasibility of a Metabolic Grading System. Journal of Nuclear Medicine, 2014, 55, 1260-1266.	5.0	76
8	Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiologica, 2011, 52, 1009-1014.	1.1	71
9	Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 852-863.	6.4	68
10	EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discovery, 2019, 9, 264-281.	9.4	57
11	Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 79-88.	6.4	54
12	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clinical Cancer Research, 2021, 27, 3595-3601.	7.0	53
13	Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2019, 60, 9-15.	5.0	45
14	⁶⁸Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics, 2020, 10, 2273-2283.	10.0	45
15	Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer, 2014, 110, 1155-1162.	6.4	42
16	Iodine Symporter Targeting with ¹²⁴I/¹³¹I Theranostics. Journal of Nuclear Medicine, 2017, 58, 34S-38S.	5.0	39
17	Correlation of BRAF^{V600E} Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study. Journal of Nuclear Medicine, 2015, 56, 662-667.	5.0	37
18	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer and Prostatic Diseases, 2021, 24, 423-430.	3.9	37

#	Article	IF	Citations
19	Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1862-1868.	6.4	36
20	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 460-469.	6.4	36
21	Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. Archives of Gynecology and Obstetrics, 2014, 290, 1023-1030.	1.7	35
22	Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis. Annals of Nuclear Medicine, 2014, 28, 405-410.	2.2	35
23	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e7-729.e16.	1.6	34
24	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer, 2020, 20, 884.	2.6	32
25	Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Clinical Cancer Research, 2022, 28, 4194-4202.	7.0	28
26	Effects of Rosiglitazone on Radioiodine Negative and Progressive Differentiated Thyroid Carcinoma as Assessed by 124I PET/CT Imaging. Clinical Nuclear Medicine, 2012, 37, e47-e52.	1.3	26
27	Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Research, 2013, 3, 82.	2.5	26
28	Combined PET Imaging and Diffusion-Weighted Imaging of Intermediate and High-Risk Primary Prostate Carcinomas with Simultaneous [18F] Choline PET/MRI. PLoS ONE, 2014, 9, e101571.	2.5	26
29	Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer. Thyroid, 2016, 26, 1712-1718.	4.5	26
30	Head-to-Head Comparison of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10â€“Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1258-1263.	5.0	26
31	[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1101-1112.	6.4	25
32	Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies. Annals of Nuclear Medicine, 2012, 26, 723-729.	2.2	23
33	Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1211-1218.	6.4	23
34	Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by ¹⁸F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials. Journal of Nuclear Medicine, 2012, 53, 1836-1846.	5.0	22
35	18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nuklearmedizin - NuclearMedicine, 2013, 52, 198-203.	0.7	22
36	89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2064-2076.	6.4	22

#	Article	IF	Citations
37	The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 235-252.	0.7	20
38	Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany. Endocrine Practice, 2015, 21, 122-127.	2.1	19
39	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	3.9	19
40	Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy 124I PET/CT imaging. EJNMMI Physics, 2014, 1, 100.	2.7	17
41	Diagnostic accuracy of 18Fâ€“FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. BMC Cancer, 2017, 17, 887.	2.6	16
42	Diagnosis of hyperfunctional thyroidn odules. Nuklearmedizin - NuclearMedicine, 2014, 53, 173-177.	0.7	16
43	[¹⁷⁷Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.. Journal of Clinical Oncology, 2022, 40, 5001-5001.	1.6	15
44	Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer. Journal of Nuclear Medicine, 2018, 59, 780-786.	5.0	14
45	Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference. EJNMMI Physics, 2018, 5, 13.	2.7	14
46	Pioglitazone therapy in progressive differentiated thyroid carcinoma. Nuklearmedizin - NuclearMedicine, 2012, 51, 111-115.	0.7	14
47	Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer. Journal of Molecular Endocrinology, 2017, 59, R141-R154.	2.5	13
48	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Practical Radiation Oncology, 2021, 11, 202-211.	2.1	13
49	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials, 2021, 22, 768.	1.6	13
50	124I-PET/CT images of differentiated thyroid cancer patients. Nuklearmedizin - NuclearMedicine, 2012, 51, 213-216.	0.7	10
51	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocrine-Related Cancer, 2021, 28, 391-402.	3.1	10
52	Time Course of Tumor SUV in ¹⁸F-FDG PET of Breast Cancer: Presentation of a Simple Model Using a Single Reference Point for Time Corrections of Tumor SUVs. Journal of Nuclear Medicine, 2011, 52, 18-23.	5.0	9
53	Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in nonâ€medullary thyroid cancer. Cellular Oncology (Dordrecht), 2021, 44, 611-625.	4.4	8
54	18F-fluoride PET/CT for bone scanning. Nuklearmedizin - NuclearMedicine, 2012, 51, 84-87.	0.7	8

#	Article	IF	Citations
55	Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin. Nuklearmedizin - NuclearMedicine, 2012, 51, 217-222.	0.7	7
56	Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy â€“ A German position paper from Surgery and Nuclear Medicine. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	7
57	Impact of dual-energy CT prior to radioembolization (RE). Acta Radiologica, 2015, 56, 1293-1299.	1.1	5
58	Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. Nuclear Medicine Communications, 2018, 39, 457-464.	1.1	5
59	Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. Cancers, 2021, 13, 4193.	3.7	5
60	Research Highlight: ⁶⁸Ga-PSMA-11 PET Imaging for Pelvic Nodal Metastasis in Prostate Cancer. Korean Journal of Radiology, 2022, 23, 293.	3.4	5
61	Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial Experience. European Urology Focus, 2022, 8, 1802-1808.	3.1	5
62	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. Cancers, 2020, 12, 3756.	3.7	4
63	Success rate of repeated fine needle aspiration biopsy of clinically suspicious thyroid nodules. Nuklearmedizin - NuclearMedicine, 2012, 51, 116-118.	0.7	4
64	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 250-264.	0.7	4
65	Spatial Reconstruction of Human Thyroid based on Ultrasound and CT Image Data Fusion. Biomedizinische Technik, 2013, 58 Suppl 1, .	0.8	2
66	Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma CellsIn Vitro. In Vivo, 2021, 35, 721-729.	1.3	2
67	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	2
68	Ultrasound-Guided Fine-Needle Aspiration Biopsy of Clinically Suspicious Thyroid Nodules with an Automatic Aspirator: A Novel Technique. Thyroid, 2012, 22, 695-698.	4.5	1
69	68Gaâ€“Prostate-Specific Membrane Antigenâ€“Avid Malignant Pleural Effusion in a Patient With Metastatic Adenoid Cystic Carcinoma and Concordance With 18F-FDG PET/CT. Clinical Nuclear Medicine, 2022, 47, 140-141.	1.3	1
70	An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. Cancers, 2022, 14, 2076.	3.7	1
71	Imaging of Differentiated Thyroid Cancer with Iodine-124 and F-18-FDG. , 2019, , 199-204.		0
72	Ultrasound-guided Fine Needle Aspiration Biopsy (FNAB) of suspicious thyroid nodules with an automatic aspirator: a novel technique. Thyroid, 0, , 120216081232002.	4.5	0

#	Article	IF	Citations
73	Abstract 892: Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream inputs from mTOR. , 2016, , .		0
74	PET imaging in thyroid cancer. , 2022, , .		0